MYRIAD GENETICS INC (MYGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MYGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MYGN | Director; President, Lilly Research Laboratories, Chief Scientific Officer at Eli Lilly and Company; President of Lilly Research Laboratories, President of Lilly Immunology, and Chief Scientific Officer | 52 | ["Finance and Accounting","Leadership","HealthcareIndustry","Research andDevelopment","M.D. from the Perelman School of Medicine at the University of Pennsylvania","Ph.D. in neuroscience from the University of Pennsylvania","B.S. in molecular biophysics and biochemistry from Yale University","Chief Executive Officer of Avid Radiopharmaceuticals Inc.","Extensive medical and scientific background","Significant business and management expertise in pharmaceutical industry","Background as a neuropathologist","Experience in neuroscience and diagnostics for neuropsychiatric conditions"] | ["CHCC","RPIC"] | 2026 |
Biography sourced from the proxy statement filing.
Daniel M. Skovronsky, M.D., Ph.D. has served as a director of Myriad since July 2020. Dr. Skovronsky currently serves as President of Lilly Research Laboratories, President of Lilly Immunology, and Chief Scientific Officer at Eli Lilly and Company. Previously, he served as Chief Executive Officer of Avid Radiopharmaceuticals Inc., a company he founded in 2004. Dr. Skovronsky earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania, his Ph.D. in neuroscience from the University of Pennsylvania, and a B.S. in molecular biophysics and biochemistry from Yale University. The Board has determined that Dr. Skovronsky should serve on the Board based on his extensive medical and scientific background, which provides the Board with expertise in developing predictive, personalized, and prognostic testing products. Dr. Skovronsky provides the Board with significant business and management expertise from his senior leadership roles at a major pharmaceutical company, particularly in research and development. His background as a neuropathologist and his extensive experience in neuroscience further provides the Board with specialized expertise in developing and commercializing diagnostics for neuropsychiatric and other complex medical conditions. As a director, Dr. Skovronsky has made significant contributions to Myriad's research and product development efforts, and long-term growth strategy. Age: 52 Director Since: 2020 Committees: